Search results for "acids"

showing 10 items of 3520 documents

Effectiveness of cascade filtration plasmapheresis in two patients affected by familial hypercholesterolemia

1995

Hypercholesterolemia has been recognised as a primary risk factor for coronary heart disease. Reduction of plasma levels of total and LDL cholesterol has been shown to decrease coronary atherosclerosis. Plasmapheresis represents an useful non-pharmacological tool to treat severe hypercholesterolemias. We have evaluated the effectiveness of a system of plasmapheresis using a cascade filtration method in two young male subjects (aged 16 and 26 years) with homozygous familial hypercholesterolemia. Both showed severe coronary atherosclerosis as determined by angiography. Procedures were performed at intervals of 7 days in each case. We observed a mean reduction of plasma levels of total cholest…

AdultMalemedicine.medical_specialtyAdolescentApolipoprotein Bmedicine.medical_treatmentFamilial hypercholesterolemiaFibrinogenGastroenterologyHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicinemedicineHumansHyperlipoproteinemia Type IIRisk factorCoronary atherosclerosisbiologybusiness.industryCholesterolCholesterol LDLPlasmapheresisHematologyGeneral Medicinemedicine.diseaseEndocrinologychemistrybiology.proteinlipids (amino acids peptides and proteins)PlasmapheresisbusinessFiltrationmedicine.drugJournal of Clinical Apheresis
researchProduct

Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-media…

2011

Dalcetrapib increases high-density lipoprotein cholesterol (HDL-C) levels through effects on cholesteryl ester transfer protein (CETP). As part of the dalcetrapib dal-HEART clinical trial programme, the efficacy and safety of dalcetrapib is assessed in coronary heart disease (CHD) patients in the dal-VESSEL study (ClinicalTrials.gov identifier: NCT00655538), the design and methods of which are presented here. RESEARCH DESIGN AND STUDY METHOD: Men and women with CHD or CHD risk equivalent, with HDL-C levels50  mg/dL were recruited for a 36-week, double-blinded, placebo-controlled trial. After a pre-randomisation phase of up to 8 weeks, patients received dalcetrapib 600  mg/day or placebo in …

AdultMalemedicine.medical_specialtyAdolescentBrachial ArteryDalcetrapibCoronary DiseaseAtherosclerosis CETP inhibition Endothelial function Flow-mediated dilatation ester transfer protein density-lipoprotein cholesterol off-target toxicity cardiovascular-disease dependent vasodilation coronary risk nitric-oxide torcetrapib atherosclerosis cetpModels BiologicalPlaceboschemistry.chemical_compoundYoung AdultDouble-Blind Methodmedicine.arteryInternal medicineCholesterylester transfer proteinmedicineHumansSulfhydryl CompoundsBrachial arteryLipoprotein cholesterolFlow mediated vasodilatationAgedRationalizationbiologybusiness.industryAnticholesteremic AgentsEstersGeneral MedicineCetp inhibitionMiddle AgedAmidesCoronary heart diseaseClinical trialVasodilationTreatment OutcomechemistryRegional Blood FlowResearch DesignCardiologybiology.proteinlipids (amino acids peptides and proteins)FemaleEndothelium VascularbusinessAlgorithms
researchProduct

Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level

2014

Patients with diabetes caused by single-gene mutations generally exhibit an altered course of diabetes. Those with mutations of the glucokinase gene (GCK-MODY) show good metabolic control and low risk of cardiovascular complications despite paradoxically lowered high-density lipoprotein (HDL) cholesterol levels. In order to investigate the matter, we analyzed the composition of low-density lipoprotein (LDL) and HDL subpopulations in such individuals. The LipoPrint(©) system (Quantimetrix, USA) based on non-denaturing, linear polyacrylamide gel electrophoresis was used to separate and measure LDL and HDL subclasses in fresh-frozen serum samples from patients with mutations of glucokinase or …

AdultMalemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismBiologyLipid subpopulationsYoung Adultchemistry.chemical_compoundEndocrinologyMonogenic diabetesInternal medicineDiabetes mellitusGlucokinasemedicineInternal MedicineHumansHepatocyte Nuclear Factor 1-alphaChildType 1 diabetesmedicine.diagnostic_testCholesterolGlucokinaseCholesterol HDLCase-control studynutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaseLipoproteins LDLDiabetes Mellitus Type 1EndocrinologychemistryCase-Control StudiesMetabolic control analysisMODYOriginal ArticleFemalelipids (amino acids peptides and proteins)Lipoproteins HDLLipid profileLipoproteinActa Diabetologica
researchProduct

Lipid subclasses profiles and oxidative stress in aggressive periodontitis before and after treatment

2015

Background and Objective: Associations between dyslipidaemia, oxidative stress and periodontitis have emerged in recent years. However, there is a lack of studies investigating these associations in aggressive periodontitis (AgP) cases. The aim of this study was to investigate the lipid and oxidative stress profiles in patients with AgP, and to relate them to clinical variables and interleukin (IL)-6 genetic variants. Material and Methods: Twelve non-smoking Caucasian patients with AgP selected based on their IL6 haplotypes underwent periodontal non-surgical and surgical treatment. Peripheral blood samples taken at baseline and at six different time-points after treatment were processed to …

AdultMalemedicine.medical_specialtyAdolescentEuropean Continental Ancestry GroupLongitudinal Studiemedicine.disease_causeWhite Peoplechemistry.chemical_compoundYoung AdultGeneticInternal medicinemedicineHaplotypeAggressive periodontitisHumansLongitudinal StudiesPeriodontitismedicine.diagnostic_testCholesterolbusiness.industryInterleukin-6PeriodontitiOxidative Stress.BiomarkerLipidmedicine.diseaseLipidsAggressive PeriodontitiOxidative StressEndocrinologyTreatment OutcomechemistryAggressive PeriodontitisHaplotypesPeriodonticsOxidative strelipids (amino acids peptides and proteins)FemaleMetabolic syndromebusinessLipid profileDyslipidemiaOxidative stressBiomarkersLipoproteinHuman
researchProduct

Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: The di@bet.es study

2013

Abstract Introduction Dyslipidemia is a significant contributor to the elevated CVD risk observed in type 2 diabetes mellitus. We assessed the prevalence of dyslipidemia and its association with glucose metabolism status in a representative sample of the adult population in Spain and the percentage of subjects at guideline-recommended LDL-C goals. Material and methods The di@bet.es study is a national, cross-sectional population-based survey of 5728 adults. Results A total of 4776 subjects were studied. Dyslipidemia was diagnosed in 56.8% of subjects; only 13.2% of subjects were treated with lipid lowering drugs. Lipid abnormalities were found in 56.8% of Spanish adults: 23.3% with high LDL…

AdultMalemedicine.medical_specialtyAdolescentPopulationAdult populationCarbohydrate metabolismPrediabetic StateYoung AdultRisk FactorsInternal medicinePlasma lipidsPrevalencemedicineHumansPharmacology (medical)educationAgedDyslipidemiasHypolipidemic Agentseducation.field_of_studybusiness.industryCholesterol HDLType 2 Diabetes MellitusCholesterol LDLMiddle Agedmedicine.diseaseSpanish populationCross-Sectional StudiesGlucoseEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesSpainFemalelipids (amino acids peptides and proteins)Lipid loweringCardiology and Cardiovascular MedicinebusinessDyslipidemiaClínica e Investigación en Arteriosclerosis
researchProduct

Efficacy of a Spray Compound Containing a Pool of Collagen Precursor Synthetic Amino Acids (L-Proline, L-Leucine, L-Lysine and Glycine) Combined with…

2010

Oral mucositis (OM) is a very frequent and potentially severe complication experienced by patients receiving chemotherapy and/or radiotherapy, which often leads to significant morbidity and mortality, and decreased quality of life, and is very costly. Despite its severity and prevalence, there is no standard recognised management today. The aim of this open clinical trial is to evaluate the efficacy and compliance of a new spray compound containing sodium hyaluronate (SH) and a pool of collagen precursor amino acids (AAs) combined with sodium hyaluronate (SH) to manage radio/chemotherapy-induced OM. Twenty-seven consecutive patients with OM were treated according to the manufacturer's inst…

AdultMalemedicine.medical_specialtyAdolescentProlineVisual analogue scalemedicine.medical_treatmentImmunologySodium hyaluronateGlycineAntineoplastic AgentsGastroenterologyLesionchemistry.chemical_compoundSettore MED/28 - Malattie OdontostomatologicheLeucineInternal medicinemedicineMucositisHumansImmunology and Allergyhyaluronic acid amino acids oral mucositis oral ulcer spray compound pain wound healingAmino AcidsHyaluronic AcidAdverse effectStomatitisAgedPain MeasurementAged 80 and overPharmacologyStomatitisChemotherapyRadiotherapybusiness.industryLysineMiddle Agedmedicine.diseaseSurgeryClinical trialchemistryHead and Neck NeoplasmsFemaleCollagenmedicine.symptombusinessInternational Journal of Immunopathology and Pharmacology
researchProduct

Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome

2010

Background: Although dyslipidemia is common in the polycystic ovary syndrome (PCOS), current diagnostic guidelines suggest to evaluate only plasma HDL-cholesterol and triglyceride concentrations, assuming that, in this disorder, cardiovascular risk is mainly due to the presence of the metabolic syndrome (MS). In the US, MS has been found in up to 50% of PCOS, but in other countries its prevalence is lower. Methods: We compared the prevalence of MS with that of increased LDL- and non-HDL-cholesterol levels in 350 Mediterranean PCOS women (244 anovulatory and 106 ovulatory), and 95 normo-weight and 90 body mass index (BMI)-matched controls. Results: The prevalence of MS was 7.1% in PCOS, high…

AdultMalemedicine.medical_specialtyAdolescentendocrine system diseasesEndocrinology Diabetes and MetabolismYoung Adultchemistry.chemical_compoundEndocrinologyRisk FactorsInternal medicinemedicineHumansIncreased ldlTriglyceridesMetabolic SyndromeTriglyceridebusiness.industryCholesterol HDLnutritional and metabolic diseasesCholesterol LDLPrognosismedicine.diseaseLipidsPolycystic ovaryCholesterolEndocrinologychemistryCardiovascular DiseasesCase-Control StudiesFemalelipids (amino acids peptides and proteins)Metabolic syndromebusinessBody mass indexBiomarkersDyslipidemiaFollow-Up StudiesPolycystic Ovary SyndromeJournal of Endocrinological Investigation
researchProduct

Benign oral vascular lesions treated by sclerotherapy with ethanolamine oleate : a retrospective study of 43 patients

2017

Background Although sclerotherapy is a common treatment for benign oral vascular lesions, there is no well-standardized protocol for this purpose. The aim of the present study was to describe the clinical characteristics of patients treated by sclerotherapy with ethanolamine oleate (EO), in order to contribute to a better understanding of this technique. Material and Methods Medical records and images of 90 patients treated by the same sclerotherapy protocol were retrieved and analysed. Thus, 43 cases with complete information were selected and described. Results The most affected age group was 41–70 years, with a female predominance and 86% of patients being Caucasian. Lips were the most a…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentOleic AcidsGastroenterologyCongenital AbnormalitiesLesion03 medical and health sciencesYoung Adult0302 clinical medicineTongueInternal medicineSclerotherapymedicineSclerotherapyHumansYoung adultEthanolamine OleateChildGeneral DentistryAgedRetrospective StudiesMouthOral Medicine and Pathologybusiness.industryMedical recordResearchClinical appearanceRetrospective cohort study030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Sclerosing Solutionsmedicine.anatomical_structureOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASBlood VesselsSurgeryFemaleMouth Neoplasmsmedicine.symptombusinessHemangioma
researchProduct

Effects of the association of aging and obesity on lipids, lipoproteins and oxidative stress biomarkers: a comparison of older with young men.

2011

In this study, plasma lipids, lipoproteins and markers of oxidant/antioxidant status were investigated in young (n = 45) and older (n = 40) obese men and compared to those in young (n = 65) and older (n = 55) normal weight controls. The purpose was to determine whether obesity exacerbates or not lipid, lipoprotein abnormalities and oxidative stress in older men. Our findings showed that all obese patients had increased plasma triglyceride, cholesterol, LDL-cholesterol, -triglyceride and HDL-triglyceride levels concentrations compared to controls (P < 0.01). However, the younger obese men had relatively larger and accentuated changes in plasma lipids and lipoproteins than the older patients.…

AdultMalemedicine.medical_specialtyAgingLipid PeroxidesAntioxidantEndocrinology Diabetes and Metabolismmedicine.medical_treatmentLipoproteinsMedicine (miscellaneous)medicine.disease_causeAntioxidantsBody Mass IndexProtein Carbonylationchemistry.chemical_compoundInternal medicineMedicineHumansObesityAgedchemistry.chemical_classificationNutrition and DieteticsTriglyceridebusiness.industryCholesterolSuperoxide DismutaseGlutathione peroxidaseMiddle Agedmedicine.diseaseObesityLipidsOxidative StressEndocrinologychemistrylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessBody mass indexOxidative stressBiomarkersLipoproteinNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease

1992

A randomized, placebo-controlled multicenter trial was conducted to evaluate the efficacy and safety of a delayed-release formulation of 5-aminosalicylic acid (5-ASA) (Asacol; GiulianiBracco, Milan, Italy) for prevention of clinical relapse in 125 patients with inactive Crohn's disease. Patients in remission [Crohn's Disease Activity Index (CDAI) less than 150] between 3 months and 2 years were randomly allocated to receive either 800 mg 5-ASA three times daily (n = 64) or placebo (n = 61) for up to 12 months or until relapse of symptoms. Relapse was defined by a CDAI greater than 150, with a minimum increase of 100 points over the baseline value. The cumulative relapse rates were 12% in th…

AdultMalemedicine.medical_specialtyAminosalicylic acidAdolescentmedicine.medical_treatmentPlaceboGastroenterologychemistry.chemical_compoundCrohn DiseaseInternal medicineMulticenter trialHumansMedicineIleitisMesalamineAdverse effectAgedCrohn's diseaseHepatologybusiness.industryGastroenterologyBowel resectionMiddle AgedPrognosismedicine.diseaseConfidence intervalSurgeryAminosalicylic AcidschemistryPatient ComplianceFemalebusinessGastroenterology
researchProduct